GlassScriptPhysician profile
Ismat A Asad
NPI 1730403320
$2,334.40
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $203 · 2021: $1,026 · 2022: $429.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $565.77 | 2019-2022 | |
| Abbvie INC. | $395.42 | 2021-2022 | |
| Amgen INC. | $351.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $141.83 | 2019-2022 | |
| Amarin Pharma, INC. | $108.45 | 2021-2022 | |
| Pfizer INC. | $95.95 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $90.28 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $75.10 | 2019-2021 | |
| Lilly USA, LLC | $74.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.56 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.21 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $52.22 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.00 | 2022 | |
| Medtronic Vascular, INC. | $31.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $23.40 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.60 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.33 | 2019 | |
| Edwards Lifesciences Corporation | $16.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.28 | 2021 | |
| Esperion Therapeutics, INC. | $15.06 | 2022 | |
| Allergan, INC. | $13.62 | 2019 | |
| Medtronic, INC. | $12.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.28 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.98 | 2020 | |
| Metuchen Pharmaceuticals | $11.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ismat Asad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.